Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.96 |
| ▸ | GFER | P55789 | 2/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.96 |
| ▸ | GMNN | O75496 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxiepinephrine SCHEMBL29379200 | 1.00 | MAPT (1.00) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL31364234 | 0.98 | MAPT (1.00) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL7438678 | 0.98 | MAPT (0.96) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL1320882 | 0.98 | MAPT (1.00) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL6471632 | 0.96 | MAPT (0.92) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL14918907 | 0.91 | MAPT (0.83) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL28945910 | 0.89 | MAPT (0.80) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| Deoxiepinephrine SCHEMBL31078819 | 0.85 | MAPT (0.73) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| SCHEMBL14472993 | 0.84 | MAPT (0.72) | MAPTALOX15HIF1AHSD17B10MAPK1 | |
| SCHEMBL12305680 | 0.84 | MAPT (0.72) | MAPTALOX15HIF1AHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| CN-116516690-B | Fiber impregnating solution for improving bonding effect between nylon fiber and rubber and preparation method thereof | 青岛科技大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119121633-A | Aqueous phase sizing product based on catechol derivative modified polymer and rapid organic fiber modification method thereof | 上海大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118703012-B | Composite membrane suitable for Prussian blue positive electrode material, and preparation method and application thereof | 太仓中科赛诺新能源科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118703012-A | Composite membrane suitable for Prussian blue positive electrode material, and preparation method and application thereof | 太仓中科赛诺新能源科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118472550-A | Preparation method of polyolefin-cellulose composite diaphragm | 镇江汇杰智能材料科技有限公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| US-20240225978-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS | Bokman, Christine Lynn (US) | 2024-07-11 | — | — | US | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| WO-1995024919-A1 | NEW USE OF GROWTH HORMONE | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 1995-09-21 | — | — | WO | claimed |
| US-5011608-A | Biogenic amine assay using HPLC-ECD | DAMJANOVIC DRAGANA (CA) | 1991-04-30 | — | — | US | claimed |
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | claimed |
| EP-0132880-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING EPININE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Simes S.p.A. (IT) | 1988-06-15 | — | — | EP | claimed |
| US-4628064-A | Epinine and the therapeutic use thereof | SIMES, SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) | 1986-12-09 | — | — | US | claimed |
| EP-0132880-A1 | Pharmaceutical compositions containing epinine or a pharmaceutically acceptable salt thereof | Simes S.p.A. (IT) | 1985-02-13 | — | — | EP | claimed |
| US-4218470-A | CARDIOCIRCULATORY ANALEPTICS | SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) | 1980-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CYP21A2, HSD11B2, CA2 | MAPT 2161/4885ALOX15 711/4885HIF1A 436/4885 |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | MAPT 3368/4885ALOX15 290/4885HIF1A 668/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | MAPT 4/4885ALOX15 886/4885HIF1A 2301/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | MAPT 3670/4885ALOX15 663/4885HIF1A 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.